Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects

Inclusion Criteria: * Provide informed consent signed by study patient and investigator; * Subjects with Health Social Identification Number; * Allergic subjects with rhinitis with or without asthma and with or without conjunctivitis symptoms with proof of sensitisation to an inhalant allergy, either house dust mite ( Dermatophagoides pteronyssinus) or birch pollen by a positive skin prick test (SPT) with a wheal diameter ≥3 mm as compared to negative control. The clinical response against the culprit allergen will be assessed by a positive nasal allergen provocation test. (patients must not have clinical symptoms corresponding to both sensitization). * Non-allergic subjects with proof of lack of sensitisation to any of the above referred allergens by a negative conventional skin prick test less than 2 years. * Normal lung function as judged by investigator with FEV 1 and FEV 1/FVC ≥ 70% of predicted * Willing and able to comply with clinic visits and study-related procedures; * Able to understand and complete study-related questionnaires. Exclusion Criteria: * Skin pathology like chronic or exuberant urticaria, dermographism, chronic dermatitis that needs daily treatment; * Any skin abnormalities, which could negatively - in the opinion of the investigator - affect the test results, including large scars and tattoos on the forearm ; * Patients with clinical symptoms corresponding to both sensitization to birch and house dust mite * Use of antihistaminic medication \< 7 days before the start of the study; * Use of tricyclic antidepressants (antihistamine activity) \< 7 days before the start of the study; * Use of topical (on the forearm) or systemic corticoids \< 7 days before the start of the study; * Use of any monoclonal antibodies such as omalizumab, dupilumab, mepolizumab \< 6 months before the start of the study; * Use of oral systemic corticosteroids within 4 weeks prior to screening * Use of intramuscular systemic corticosteroids within 3 months prior to screening * Use of allergen immunotherapy for the allergen tested (\<2 y) or another inhalant allergen; * Pregnancy or breastfeeding; * Women without highly effective contraception (hormonal contraception, intrauterine device, bilateral tubal occlusion/ligation, vasectomized partner, sexual abstinence) at least one month prior to inclusion and during the study; * Incapacitated subjects; * Subjects who do not speak the local language (French); * Subjects who cannot read or write.